Tag: Viral Genetics and Evolution

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes

AI SummaryThe content discusses a study focused on investigating treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair (HRR) genes, particularly BRCA1/2. While germline BRCA mutations have been linked to poor outcomes in prostate cancer, the association between somatic/germline alterations in HRR genes… Continue reading Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes

[ASAP] Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors

AI SummaryThis article discusses the discovery and proof of concept of potent dual inhibitors of Polθ and PARP for the treatment of homologous recombination-deficient tumors. The research focuses on developing a more efficient treatment strategy for cancers with DNA repair deficiencies by targeting multiple pathways simultaneously. The outcomes of this research could lead to the… Continue reading [ASAP] Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors

Genotype F of Echovirus 25 with multiple recombination pattern have been persistently and extensively circulating in Chinese mainland

AI SummarySummary: This study examines the molecular epidemiology and evolution of Echovirus 25 (E25) in China. The study finds that E25 genotype F is the dominant genotype in China and identifies multiple recombination patterns and a positive selector site in this genotype. The study provides insights into the transmission routes and evolution characteristics of E25… Continue reading Genotype F of Echovirus 25 with multiple recombination pattern have been persistently and extensively circulating in Chinese mainland

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer

AI SummaryThis study focused on combining PARP and MEK inhibition, with or without anti-PD-L1 treatment, for patients with BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. Results showed that the doublet and triplet therapy regimens demonstrated promising activity, particularly in patients with HRDsig-positive tumors. Additionally, NF1 and MKNK1 mutations were associated with sustained benefit in specific treatment… Continue reading Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer

Abstract Background This phase 1b study (ClinicalTrials.gov identifier NCT03695380) evaluated regimens combining PARP and MEK inhibition, with or without PD-L1 inhibition, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer (PSROC). Methods Patients with PSROC who had received one or two prior treatment lines were treated with 28-day cycles of cobimetinib 60 mg daily (days 1–21) plus niraparib… Continue reading Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer